Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Sunday 15 November →